1|0|Public
50|$|<b>Gevotroline</b> (WY-47,384) is an {{atypical}} antipsychotic with a tricyclic structure {{which was}} under {{development for the}} treatment of schizophrenia by Wyeth-Ayerst. It acts as a balanced, modest affinity D2 and 5-HT2 receptor antagonist and also possesses high affinity for the sigma receptor. It was well-tolerated and showed efficacy in phase II clinical trials but was never marketed.|$|E

